| HOME >> BIOLOGY >> TECHNOLOGY |
response (<50 percent improvement in PASI response relative to
baseline, with a minimum six point increase in PASI score compared to
week 33) compared to patients on placebo (28 percent).
-- In CHAMPION, a pivotal 16-week study evaluating 271 psoriasis patients
from eight European countries and Canada, HUMIRA-treated patients
experienced a significant reduction in the signs and symptoms of their
disease compared with methotrexate or placebo-treated patients, with
more than twice the percentage (80 percent) of patients treated with
HUMIRA achieving a PASI 75 response compared to patients treated with
methotrexate (36 percent), a standard systemic treatment for
psoriasis, and more than four times the percentage of patients treated
with placebo (19 percent).
Nearly 17 percent of patients treated with HUMIRA achieved a PASI 100
response at week 16, compared to 7 percent of patients receiving
methotrexate and 2 percent of patients receiving placebo. In
addition, a mean percentage PASI improvement of 57 percent was
achieved at week four in patients receiving HUMIRA, compared to
baseline.
The most commonly reported adverse events in HUMIRA psoriasis trials were nasopharyngitis (inflammation of the nose and pharynx), upper respiratory tract infection and headache.
More Information About Psoriasis
Psoriasis is a chronic autoimmune disease that speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form of psoriasis appears as red, raised areas of skin covered with flaky white scales, which may itch or burn. Psoriasis most commonly appears on the scalp, knees, elbows, lower back, hands and feet, though it can develop anywhere on the skin. It may even occur in the fingernails and toenails.
While psoriasis can occur in people of all ages, it typic
'/>"/>
| SOURCE Abbott Copyright©2007 PR Newswire. All rights reserved |
Related biology technology :
1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
3. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
4. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
5. IsoTis Receives FDA Clearance for Accell Family of Products
6. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
7. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
8. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
9. XTL Receives Staff Letter From NASDAQ
10. XTL Receives Staff Letter From NASDAQ; XTL may Transfer its ADR Listing to the NASDAQ Capital Market
11. Hemo-Stream(TM) Chronic Dialysis Catheter Receives FDA Clearance
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |